June 26, 2017 2:02 AM ET

Biotechnology

Company Overview of Oncimmune Holdings plc

Company Overview

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer. It develops autoantibody assay technologies that have the potential to early detection a range of solid cancer tumor types. The company offers EarlyCDT-Lung, a blood test that is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. It also engages in the development of EarlyCDT tests for liver and ovarian cancer. The company was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Clinical Sciences Building

Nottingham City Hospital

Hucknall Road

Nottingham,  NG5 1PB

United Kingdom

Founded in 2015

33 Employees

Phone:

44 1158 231 869

Fax:

44 1158 231 958

Key Executives for Oncimmune Holdings plc

Chief Executive Officer and Director
Total Annual Compensation: 200.0K GBP
Chief Financial Officer, Company Secretary and Executive Director
Age: 48
Compensation as of Fiscal Year 2016.

Oncimmune Holdings plc Key Developments

Oncimmune Holdings plc Signs First Distribution Agreements for EarlyCDT®-Lung Kit with Best Medical Opinion and Dow Biomedica

Oncimmune Holdings plc announced that it has signed two new exclusive distribution agreements for its EarlyCDT®-Lung test with Best Medical Opinion and Dow Biomedica/Biodiscovery in Israel and Korea respectively. The test in "kit" form is in the final stages of validation for its CE mark and is expected to be available shortly. Both agreements allow for sales as a central laboratory test in the interim. The distribution agreement with Best Medical is for an initial term of five years effective 1 May 2017. The agreement with Dow Biomedica/Biodiscovery will be for an initial term of four years, also effective 1 May 2017. Biodiscovery will be the importer and holder of the registration license. The two agreements include minimum sales commitments from year two which increase annually over the initial terms of the agreements amounting to, in aggregate of £5.2 million. First sales are expected to commence late in 2017/early 2018.

Oncimmune Holdings plc Appoints Shane Smith as Senior Vice President, Market Access & Reimbursement Oncimmune (USA)

Oncimmune Holdings plc announced the appointment of Shane Smith as Senior Vice President, Market Access & Reimbursement Oncimmune (USA). Most recently, Shane was Vice President, Market Access & Reimbursement, Lineagen Inc. in Salt Lake City, UT where he focused on coverage and value-based reimbursement for Lineagen's portfolio.

Oncimmune Holdings plc Reports Unaudited Consolidated Earnings Results for the Half Year Ended November 30, 2016

Oncimmune Holdings plc reported unaudited consolidated earnings results for the half year ended November 30, 2016. For the year, the company reported revenue of £114,000 against £272,000 a year ago. Operating loss was £2,438,000 against £2,241,000 a year ago. Loss on ordinary activities before taxation was £2,476,000 against £1,096,000 a year ago. Total comprehensive loss attributable to owner of the parent was £2,322,000 against £841,000 a year ago. Basic and diluted loss per share was 0.05 pence against 0.04 pence a year ago. Net cash used in operating activities was £2,468,000 against £1,051,000 a year ago. Purchase of property, plant and equipment was £1,000 against £270,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oncimmune Holdings plc, please visit www.oncimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.